Meflam (Mefenamic Acid)

Mefenamic acid blocks both COX‑1 and COX‑2 enzymes, which are responsible for producing prostaglandins that mediate pain, fever and inflammation. By lowering prostaglandin levels, the drug diminishes peripheral sensitisation of pain receptors and reduces inflammatory swelling.

The appropriate dose of Meflam is determined by the prescribing clinician based on the patient’s condition, age, weight and overall health. Dosage regimens may differ, so patients should follow the specific instructions provided by their healthcare professional.

Safety of mefenamic acid in pregnancy and lactation has not been fully established. It is generally avoided during the first trimester and used only if the potential benefit outweighs the risk. Breastfeeding mothers should consult their physician before use.

To request Meflam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Meflam (mefenamic acid) is a non‑selective COX inhibitor similar to ibuprofen or naproxen, but it has a slightly different pharmacokinetic profile and may be preferred for dysmenorrhea. Choice of NSAID depends on efficacy, tolerability, patient comorbidities and physician preference.

Meflam should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency.

Meflam is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with meals may reduce gastrointestinal irritation. Patients should swallow the tablet whole and not crush or chew it.

Serious risks include gastrointestinal ulceration or bleeding, renal impairment, severe skin reactions such as Stevens‑Johnson syndrome, and rare but life‑threatening allergic reactions (anaphylaxis). Patients should seek immediate medical attention if they notice signs of these conditions.

Meflam is contraindicated in individuals with known hypersensitivity to mefenamic acid or other NSAIDs, active gastrointestinal ulcer disease, severe renal or hepatic impairment, and in patients taking anticoagulants where bleeding risk is unacceptable. Clinicians should evaluate each patient’s medical history before prescribing.